Shakespeare once asked, “What’s in a name? Would a rose by any other name smell as sweet?” And in the case of Denali, would a ...
Denali eyes approval after Hunter syndrome drug clears safety measures, reduces biomarkers in open-label study By Darren Incorvaia Feb 6, 2025 12:05pm ...
A Denali Therapeutics drug for the rare enzyme deficiency Hunter syndrome is still in pivotal testing, but the company has guidance from the FDA on a pathway to get this therapy to the market sooner.
Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24 ...